Gastrin

Cancer Advances, Inc. Announces Issuance of New U.S. Patent

Retrieved on: 
Tuesday, February 28, 2023
Cancer, Survival, Fibrosis, Pancreatic cancer, Gastrointestinal cancer, Research, Neoplasm, Patient, Patent, Therapy, PAS, GI, Tumor microenvironment, Antibody, Humoral immunity, Pharmaceutical industry, Gastrin

DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S. Patent and Trademark Office has issued new patent No.

Key Points: 
  • DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S. Patent and Trademark Office has issued new patent No.
  • The new patent titled “Compositions and Methods for Inducing Humoral and Cellular Immunities against Tumors and Cancer” covers a method for treating and/or preventing and/or inhibiting development of a tumor and/or a cancer associated with gastrin signaling in a subject.
  • The novel IP further covers methods for treatment of GI cancer by administering PAS followed by an immune checkpoint inhibitor.
  • Cancer Advances plans to seek approval for PAS in the treatment of gastric and pancreatic cancers.

IND approval from the US FDA for Phase II SAR-Bombesin imaging trial in prostate cancer

Retrieved on: 
Monday, June 6, 2022
Pro-Gastrin-Releasing-Peptide, Executive, PSMA, Society, Clarity, St Vincent's Hospital, Sydney, Breast cancer, Cancer, ASCO, Hope, Annual general meeting, Prostate cancer, US FDA, Prostate, FDA, American Society of Clinical Oncology, Patient, CT, BCR, Better Access Scheme, Gastrin, SABRE, Population, Recurrence, NPR1, Prostate cancer screening, ASX, MRI, Safety, Medical imaging, IND

SYDNEY, June 6, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address growing medical needs in oncology, announces the approval of its Investigational New Drug (IND) application by the United States Food and Drug Administration (US FDA) to evaluate its SAR-Bombesin product as an imaging agent in prostate cancer patients that are Prostate-Specific Membrane Antigen (PSMA)-negative.

Key Points: 
  • Clarity's Executive Chairman, Dr Alan Taylor, commented,"Receiving clearance from the FDA on the imaging trial with SAR-Bombesin is yet another significant milestone for Clarity.
  • SABRE, which derives from "Copper-64 SAR-Bombesin in Biochemical REcurrence of Prostate Cancer trial", is a multi-center, single arm, non-randomised, open-label trial in up to 50 PSMA-negative patients with known or suspected prostate cancer.
  • The primary objectives of the trial are to investigate the safety and tolerability of 64Cu SAR-Bombesin, as well as its ability to correctly detect the recurrence of prostate cancer.
  • Given the prostate cancer indication is one of the largest in oncology, there is a significant unmet medical need in this segment.

Cancer Advances, Inc. Announces Abstract at AACR

Retrieved on: 
Tuesday, March 23, 2021
Branches of biology, Anatomy, Digestive system, Organ systems, Abdomen, Cancer, Pancreatic cancer, Gastrointestinal cancer, Gastrin, Gastrointestinal tract, Pro-Gastrin-Releasing-Peptide

DURHAM, N.C., March 23, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces that an abstract will be included in the upcoming 2021 American Association of Cancer Research (AACR) Annual Meeting being held virtually from April 10-15, 2021.

Key Points: 
  • DURHAM, N.C., March 23, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces that an abstract will be included in the upcoming 2021 American Association of Cancer Research (AACR) Annual Meeting being held virtually from April 10-15, 2021.
  • PAS is a cancer vaccine that induces antibodies to gastrin, a known autocrine accelerator of certain pancreatic cancers.
  • Polyclonal Antibody Stimulator (PAS) vaccine is an immunomodulator potentially applicable in multiple cancer types including gastric, pancreatic, and colorectal.
  • Cancer Advances exclusively owns PAS and is funding and managing all aspects of the PAS gastrin vaccine program.

Cinclus Pharma Appoints Jenni Björnulfson as Chief Financial Officer

Retrieved on: 
Thursday, April 16, 2020
Branches of biology, Digestive system, Companies, Medical specialties, AstraZeneca, Gastrin, Gastric acid, Novartis, Parietal cell, Stomach

The Swedish based company Cinclus Pharma Holding AB is the 100% owner of Cinclus Pharma AG, a research-based biotech company, based in Basel, Switzerland.

Key Points: 
  • The Swedish based company Cinclus Pharma Holding AB is the 100% owner of Cinclus Pharma AG, a research-based biotech company, based in Basel, Switzerland.
  • The management team is highly experienced in the GI area (AstraZeneca, Glaxo and Novartis).
  • X842 belongs to the P-CAB class that competitively inhibits the H+, K+-ATPase in the parietal cell and thereby controls gastric acid secretion.
  • X842 is a prodrug of linaprazan, with comprehensive data from 25 Phase I studies including more than 600 subjects.

Cinclus Pharma Appoints Jenni Björnulfson as Chief Financial Officer

Retrieved on: 
Thursday, April 16, 2020
Branches of biology, Digestive system, Companies, Medical specialties, AstraZeneca, Gastrin, Gastric acid, Novartis, Parietal cell, Stomach

The Swedish based company Cinclus Pharma Holding AB is the 100% owner of Cinclus Pharma AG, a research-based biotech company, based in Basel, Switzerland.

Key Points: 
  • The Swedish based company Cinclus Pharma Holding AB is the 100% owner of Cinclus Pharma AG, a research-based biotech company, based in Basel, Switzerland.
  • The management team is highly experienced in the GI area (AstraZeneca, Glaxo and Novartis).
  • X842 belongs to the P-CAB class that competitively inhibits the H+, K+-ATPase in the parietal cell and thereby controls gastric acid secretion.
  • X842 is a prodrug of linaprazan, with comprehensive data from 25 Phase I studies including more than 600 subjects.

Cancer Advances, Inc. Announces Poster Presentation at ASCO GI

Retrieved on: 
Wednesday, January 22, 2020
RTT, Medical specialties, Medicine, Health, Oncology, Gastrointestinal cancer, Pancreatic cancer, Tumor microenvironment, Cancer, Gastrin, Metástasis

The poster is entitled, Use of gastrin vaccine to increase gamma-delta and NKT cells and alter pancreas tumor microenvironment to improve survival.

Key Points: 
  • The poster is entitled, Use of gastrin vaccine to increase gamma-delta and NKT cells and alter pancreas tumor microenvironment to improve survival.
  • The researchers examined whether Cancer Advances Polyclonal Antibody Stimulator (PAS) vaccine could alter the tumor microenvironment (TME) of pancreatic cancer and reduce metastasis in mice.
  • Lynda Sutton, President, Cancer Advances Inc., and Jill Smith, MD, Lombardi Comprehensive Cancer Center, Georgetown University, will be available to answer questions following the presentation.
  • Cancer Advances exclusively owns PAS and is funding and managing all aspects of the PAS gastrin vaccine program.

Cancer Advances, Inc. announces new publication: “Gastrin Vaccine Improves Response to Immune Checkpoint Antibody in Murine Pancreatic Cancer by Altering the Tumor Microenvironment”, in the journal Cancer Immunology, Immunotherapy

Retrieved on: 
Monday, November 11, 2019
Medical specialties, Medicine, Branches of biology, Tumor microenvironment, Programmed cell death protein 1, Immune checkpoint, Cancer vaccine, Polyclonal antibodies, Gastrin, Cancer immunotherapy, Immune system

Polyclonal Antibody Stimulator (PAS) monotherapy elicits both a humoral and a cellular immune response when used in immune competent mice bearing pancreatic tumors.

Key Points: 
  • Polyclonal Antibody Stimulator (PAS) monotherapy elicits both a humoral and a cellular immune response when used in immune competent mice bearing pancreatic tumors.
  • The researchers set out to determine whether vaccination with Cancer Advances anti-gastrin cancer vaccine, PAS (Polyclonal Antibody Stimulator) induces a gastrin-dependent T-cell response in immune competent mice with pancreatic cancer.
  • The study also examined the impact of PAS monotherapy and PAS combined with a PD-1 immune checkpoint antibody on pancreatic tumor growth, and the tumor microenvironment.
  • Print version: Gastrin Vaccine Improves Response to Immune Checkpoint Antibody in Pancreatic Cancer by Altering the Tumor Microenvironment, Cancer Immunol Immunother.